Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6540381,bioavailability,"The bioavailability of oral pyridostigmine was 3.6%, estimated by replacing one dose with an intravenous dose amounting to 1/30 of the oral dose.",Steady state kinetics of pyridostigmine in myasthenia gravis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540381/),%,3.6,4214,DB00545,Pyridostigmine
,17015495,half-life,"Pharmacokinetic evaluation revealed a short half-life of 2.29 hours, similar to the 2.0 +/- 0.63 hours in the patients with myasthenia.",Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015495/),h,2.29,10409,DB00545,Pyridostigmine
,17015495,half-life,"Pharmacokinetic evaluation revealed a short half-life of 2.29 hours, similar to the 2.0 +/- 0.63 hours in the patients with myasthenia.",Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015495/),h,2.0,10410,DB00545,Pyridostigmine
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],991,13442,DB00545,Pyridostigmine
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],839,13443,DB00545,Pyridostigmine
,11920923,plasma Cmax,The plasma Cmax in seizure-terminated animals in this study is similar to the minimum range of plasma diazepam (200-800 ng x ml(-1)) reported to suppress seizure activity in humans.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],200-800,13444,DB00545,Pyridostigmine
,11920923,Cmax,It has been reported in an earlier study that the minimum effective i.m. dose (0.1 mg x kg(-1)) required to prevent soman-induced convulsions in Rhesus monkeys produces a mean Cmax of 50 ng x ml(-1) for diazepam.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],50,13445,DB00545,Pyridostigmine
,22477197,X(1),"Multiple linear regression analysis for process optimization revealed that the optimal PBPLC was obtained when the values of X(1), X(2), and X(3) were 8, 40°C, and 4 mg/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),°c,8,16555,DB00545,Pyridostigmine
,22477197,X(2),"Multiple linear regression analysis for process optimization revealed that the optimal PBPLC was obtained when the values of X(1), X(2), and X(3) were 8, 40°C, and 4 mg/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),°c,40,16556,DB00545,Pyridostigmine
,22477197,X(3),"Multiple linear regression analysis for process optimization revealed that the optimal PBPLC was obtained when the values of X(1), X(2), and X(3) were 8, 40°C, and 4 mg/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),[mg] / [m],4,16557,DB00545,Pyridostigmine
,22477197,particle size,"The average particle size and zeta potential of PBPLC with the optimized formulation were 204.60 nm and -25.12 mV, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),nm,204.60,16558,DB00545,Pyridostigmine
,22477197,zeta potential,"The average particle size and zeta potential of PBPLC with the optimized formulation were 204.60 nm and -25.12 mV, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),mv,-,16559,DB00545,Pyridostigmine
,22477197,zeta potential,"The average particle size and zeta potential of PBPLC with the optimized formulation were 204.60 nm and -25.12 mV, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),mv,25.12,16560,DB00545,Pyridostigmine
,22477197,peak time (T(max)),"The values of pharmacokinetic parameters of PBPLC and free PB were the peak time (T(max)) 2 h vs 2 h, the maximum concentration (C(max)) 22.79 μg/mL vs 6.00 μg/mL, and the value of the area under the concentration vs time curve (AUC(0-∞)) 7128.21 μg·min/mL vs 1772.36 μg·min/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),h,2,16561,DB00545,Pyridostigmine
,22477197,maximum concentration (C(max)),"The values of pharmacokinetic parameters of PBPLC and free PB were the peak time (T(max)) 2 h vs 2 h, the maximum concentration (C(max)) 22.79 μg/mL vs 6.00 μg/mL, and the value of the area under the concentration vs time curve (AUC(0-∞)) 7128.21 μg·min/mL vs 1772.36 μg·min/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),[μg] / [ml],22.79,16562,DB00545,Pyridostigmine
,22477197,maximum concentration (C(max)),"The values of pharmacokinetic parameters of PBPLC and free PB were the peak time (T(max)) 2 h vs 2 h, the maximum concentration (C(max)) 22.79 μg/mL vs 6.00 μg/mL, and the value of the area under the concentration vs time curve (AUC(0-∞)) 7128.21 μg·min/mL vs 1772.36 μg·min/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),[μg] / [ml],6.00,16563,DB00545,Pyridostigmine
,22477197,area under the concentration vs time curve (AUC(0-∞)),"The values of pharmacokinetic parameters of PBPLC and free PB were the peak time (T(max)) 2 h vs 2 h, the maximum concentration (C(max)) 22.79 μg/mL vs 6.00 μg/mL, and the value of the area under the concentration vs time curve (AUC(0-∞)) 7128.21 μg·min/mL vs 1772.36 μg·min/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),[min·μg] / [ml],7128.21,16564,DB00545,Pyridostigmine
,22477197,area under the concentration vs time curve (AUC(0-∞)),"The values of pharmacokinetic parameters of PBPLC and free PB were the peak time (T(max)) 2 h vs 2 h, the maximum concentration (C(max)) 22.79 μg/mL vs 6.00 μg/mL, and the value of the area under the concentration vs time curve (AUC(0-∞)) 7128.21 μg·min/mL vs 1772.36 μg·min/mL, respectively.",Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477197/),[min·μg] / [ml],1772.36,16565,DB00545,Pyridostigmine
,7439266,plasma elimination half-life,"After intravenous administration of pyridostigmine 2.5 mg the plasma elimination half-life was 1.52 h, the volume of distribution was 1.43 l/kg and the plasma clearance 0.65 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),h,1.52,31154,DB00545,Pyridostigmine
,7439266,volume of distribution,"After intravenous administration of pyridostigmine 2.5 mg the plasma elimination half-life was 1.52 h, the volume of distribution was 1.43 l/kg and the plasma clearance 0.65 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),[l] / [kg],1.43,31155,DB00545,Pyridostigmine
,7439266,plasma clearance,"After intravenous administration of pyridostigmine 2.5 mg the plasma elimination half-life was 1.52 h, the volume of distribution was 1.43 l/kg and the plasma clearance 0.65 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),[l] / [h·kg],0.65,31156,DB00545,Pyridostigmine
,7439266,elimination half-life,"The pharmacokinetic constants were very similar after oral administration of pyridostigmine 120 mg; the elimination half-life was 1.78 +/- 0.24 h, the volume of distribution 1.64 +/- 0.29 l/kg and the plasma clearance was 0.66 +/- 0.22 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),h,1.78,31157,DB00545,Pyridostigmine
,7439266,volume of distribution,"The pharmacokinetic constants were very similar after oral administration of pyridostigmine 120 mg; the elimination half-life was 1.78 +/- 0.24 h, the volume of distribution 1.64 +/- 0.29 l/kg and the plasma clearance was 0.66 +/- 0.22 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),[l] / [kg],1.64,31158,DB00545,Pyridostigmine
,7439266,plasma clearance,"The pharmacokinetic constants were very similar after oral administration of pyridostigmine 120 mg; the elimination half-life was 1.78 +/- 0.24 h, the volume of distribution 1.64 +/- 0.29 l/kg and the plasma clearance was 0.66 +/- 0.22 l/kg x h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),[l] / [h·kg],0.66,31159,DB00545,Pyridostigmine
,7439266,bioavailability,The bioavailability was calculated to be 7.6 +/- 2.4%.,Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),%,7.6,31160,DB00545,Pyridostigmine
,7439266,time to reach the peak plasma concentration,"When pyridostigmine was taken together with food, the time to reach the peak plasma concentration was prolonged from 1.7 to 3.2 h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),h,1.7,31161,DB00545,Pyridostigmine
,7439266,time to reach the peak plasma concentration,"When pyridostigmine was taken together with food, the time to reach the peak plasma concentration was prolonged from 1.7 to 3.2 h.",Pharmacokinetics and oral bioavailability of pyridostigmine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439266/),h,3.2,31162,DB00545,Pyridostigmine
,19703368,apparent clearance,"The apparent clearance and volume of distribution as well as absorption rate constant of plasma pyridostigmine were estimated to be 136 l/h, 130 l and 0.68 1/h, respectively.","Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703368/),[l] / [h],136,47267,DB00545,Pyridostigmine
,19703368,volume of distribution,"The apparent clearance and volume of distribution as well as absorption rate constant of plasma pyridostigmine were estimated to be 136 l/h, 130 l and 0.68 1/h, respectively.","Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703368/),l,130,47268,DB00545,Pyridostigmine
,19703368,absorption rate constant,"The apparent clearance and volume of distribution as well as absorption rate constant of plasma pyridostigmine were estimated to be 136 l/h, 130 l and 0.68 1/h, respectively.","Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703368/),[1] / [h],0.68,47269,DB00545,Pyridostigmine
,19703368,EC50),"The maximum red blood cell AChE activity decrease (E(max)) and plasma pyridostigmine concentration producing 50% of this reduction (EC50) were estimated to be 9.32 AChE units per gram haemoglobin and 51.9 ng/ml, respectively.","Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703368/),[ng] / [ml],51.9,47270,DB00545,Pyridostigmine
not exceed,2166138,peak levels,Significant correlations between pyridostigmine concentrations and functional parameters were present in three out of 11 cases in which plasma levels changed by at least 25 ng/ml during the investigational period and peak levels did not exceed 100 ng/ml.,Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2166138/),[ng] / [ml],100,56778,DB00545,Pyridostigmine
,8310710,renal clearance,"Its renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion.",Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),[ml] / [kg·min],6.65,64883,DB00545,Pyridostigmine
,8310710,elimination,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],2,64884,DB00545,Pyridostigmine
,8310710,absorption rate constant,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],0.23,64885,DB00545,Pyridostigmine
,15198070,time to seizure termination,The mean time to seizure termination was 8.8 +/- 1.6 min.,Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,8.8,74668,DB00545,Pyridostigmine
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.4,74669,DB00545,Pyridostigmine
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.7,74670,DB00545,Pyridostigmine
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,990",74671,DB00545,Pyridostigmine
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,120",74672,DB00545,Pyridostigmine
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,1.66,74673,DB00545,Pyridostigmine
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,2.91,74674,DB00545,Pyridostigmine
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],535.1,74675,DB00545,Pyridostigmine
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],436.6,74676,DB00545,Pyridostigmine
,2991094,half-life,The half-life of pyridostigmine was between 156 and 210 minutes.,[Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991094/),min,156 and 210,84768,DB00545,Pyridostigmine
,6842398,volume of the central compartment,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],412,92560,DB00545,Pyridostigmine
,6842398,volume of distribution at steady state,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],2517,92561,DB00545,Pyridostigmine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,1.1,92562,DB00545,Pyridostigmine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,25.4,92563,DB00545,Pyridostigmine
,6842398,terminal elimination half-life,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,125,92564,DB00545,Pyridostigmine
,6842398,total clearance,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg·min],21,92565,DB00545,Pyridostigmine
,6842398,onset time,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,14,92566,DB00545,Pyridostigmine
,6842398,duration of action,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,219,92567,DB00545,Pyridostigmine
,2169210,plasma clearance,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),[ml] / [kg·min],5.9,104161,DB00545,Pyridostigmine
,2169210,plasma clearance,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),[ml] / [kg·min],12.1,104162,DB00545,Pyridostigmine
,2169210,elimination half-life,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,84.2,104163,DB00545,Pyridostigmine
,2169210,elimination half-life,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,56.6,104164,DB00545,Pyridostigmine
,2169210,maximum duration of action,The maximum duration of action of edrophonium in both groups was very brief (1.3-2.2 min).,Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,1.3-2.2,104165,DB00545,Pyridostigmine
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],6.7,107246,DB00545,Pyridostigmine
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],9.5,107247,DB00545,Pyridostigmine
,3524957,Plasma clearances,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [h·kg],0.5 to 1.0,120227,DB00545,Pyridostigmine
,3524957,apparent volumes of distribution,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [kg],0.5 to 1.7,120228,DB00545,Pyridostigmine
,3524957,plasma elimination half-lives,"Accordingly, the drugs have short plasma elimination half-lives, in the order of 30 to 90 minutes.",Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,30 to 90,120229,DB00545,Pyridostigmine
,3524957,peak plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],40 to 60,120230,DB00545,Pyridostigmine
,3524957,plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],1 to 5,120231,DB00545,Pyridostigmine
,3524957,oral bioavailability,The oral bioavailability of these hydrophilic ionised compounds is low: that of pyridostigmine is approximately 10% and the value for neostigmine is even lower.,Clinical pharmacokinetics of cholinesterase inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),%,10,120232,DB00545,Pyridostigmine
,3524957,plasma elimination half-life,This drug too is characterised by a short plasma elimination half-life of 20 to 30 minutes.,Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,20 to 30,120233,DB00545,Pyridostigmine
,3183945,apparent volume of distribution,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),[l] / [kg],1.97,122921,DB00545,Pyridostigmine
,3183945,absorption rate constant,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),1/[min],0.277,122922,DB00545,Pyridostigmine
,3183945,elimination rate constant,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),1/[min],0.0273,122923,DB00545,Pyridostigmine
,3183945,area under the curve,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),[min·ng] / [ml],1010,122924,DB00545,Pyridostigmine
,3183945,absorption rate half-life,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),min,2.41,122925,DB00545,Pyridostigmine
,3183945,elimination rate half-life,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),min,24.8,122926,DB00545,Pyridostigmine
,3183945,maximal plasma concentration (Cmax),"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),[ng] / [ml],21.3,122927,DB00545,Pyridostigmine
,3183945,time to Cmax,"The results were as follows: apparent volume of distribution = 1.97 l/kg, absorption rate constant = 0.277 min-1, elimination rate constant = 0.0273 min-1, area under the curve = 1010 ng x min/ml, absorption rate half-life = 2.41 min, elimination rate half-life = 24.8 min, maximal plasma concentration (Cmax) = 21.3 ng/ml and time to Cmax = 9.02 min.",A radioimmunoassay for pyridostigmine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183945/),min,9.02,122928,DB00545,Pyridostigmine
,22027790,C(max),"The two tablets had a C(max) of 1.83∓0.08 mg·L(-1) and 1.68∓0.03 mg·L(-1), tmax of 2.33∓0.41 h and 2.58∓0.20 h, AUC(0-24) of 15.50∓0.62 mg·h·L(-1) and 15.14∓0.30 mg·h·L(-1), AUC(0-∞) of 15.82∓0.70 mg·h·L(-1) and 15.57∓0.32 mg·h·L(-1), respectively.",[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),[mg] / [l],1.,128792,DB00545,Pyridostigmine
,22027790,tmax,"The two tablets had a C(max) of 1.83∓0.08 mg·L(-1) and 1.68∓0.03 mg·L(-1), tmax of 2.33∓0.41 h and 2.58∓0.20 h, AUC(0-24) of 15.50∓0.62 mg·h·L(-1) and 15.14∓0.30 mg·h·L(-1), AUC(0-∞) of 15.82∓0.70 mg·h·L(-1) and 15.57∓0.32 mg·h·L(-1), respectively.",[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),h,2.,128793,DB00545,Pyridostigmine
,22027790,AUC(0-24),"The two tablets had a C(max) of 1.83∓0.08 mg·L(-1) and 1.68∓0.03 mg·L(-1), tmax of 2.33∓0.41 h and 2.58∓0.20 h, AUC(0-24) of 15.50∓0.62 mg·h·L(-1) and 15.14∓0.30 mg·h·L(-1), AUC(0-∞) of 15.82∓0.70 mg·h·L(-1) and 15.57∓0.32 mg·h·L(-1), respectively.",[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),[h·mg] / [l],15.,128794,DB00545,Pyridostigmine
,22027790,AUC(0-∞),"The two tablets had a C(max) of 1.83∓0.08 mg·L(-1) and 1.68∓0.03 mg·L(-1), tmax of 2.33∓0.41 h and 2.58∓0.20 h, AUC(0-24) of 15.50∓0.62 mg·h·L(-1) and 15.14∓0.30 mg·h·L(-1), AUC(0-∞) of 15.82∓0.70 mg·h·L(-1) and 15.57∓0.32 mg·h·L(-1), respectively.",[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),[h·mg] / [l],15.,128795,DB00545,Pyridostigmine
,22027790,relative bioavailability F(0-24),The relative bioavailability F(0-24) was 102.38% and F(0-∞) was 101.61% for the dispersible tablets.,[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),%,102.38,128796,DB00545,Pyridostigmine
,22027790,F(0-∞),The relative bioavailability F(0-24) was 102.38% and F(0-∞) was 101.61% for the dispersible tablets.,[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027790/),%,101.61,128797,DB00545,Pyridostigmine
,22418070,run time,"Separation was performed on a TC-C₁₈ column (150 mm × 4.6 mm, 5 μm) using a mobile phase of methanol:10 mM ammonium acetate containing 1% formic acid (65:35, v/v) in a run time of 3.5 min.","Determination of landiolol, an ultra-short-acting β₁-receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418070/),min,3.5,167348,DB00545,Pyridostigmine
,6821619,initial half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,1.0,173568,DB00545,Pyridostigmine
,6821619,terminal half-life,"In the eight patients studied, the initial half-life was 1.0 +/- 0.3 min and the terminal half-life was 46.4 +/- 6.5 min (mean +/- SEM).",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),min,46.4,173569,DB00545,Pyridostigmine
,6821619,Total body clearance,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg·min],8.7,173570,DB00545,Pyridostigmine
,6821619,total apparent volume of distribution,"Total body clearance of pyridostigmine was 8.7 +/- 1.5 ml min-1 kg-1, and the total apparent volume of distribution was 536 +/- 80 ml kg-1.",Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821619/),[ml] / [kg],536,173571,DB00545,Pyridostigmine
,16719539,constant rate,The remainder is released at a constant rate of approximately 5 microg/hour.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[μg] / [h],5,174190,DB00545,Pyridostigmine
,16719539,steady state,TTS-S attains that concentration after 6 hours; a steady state of about 100 pg/mL is achieved 8-12 hours after application.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[pg] / [ml],100,174191,DB00545,Pyridostigmine
,7329157,Maximum plasma concentrations,Maximum plasma concentrations of pyridostigmine in the first and second groups of patients ranged from 12.4 to 64.5 ng per ml and 15.3 to 144.0 ng per ml respectively.,The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329157/),[ng] / [ml],12.4 to 64.5,175641,DB00545,Pyridostigmine
,7329157,Maximum plasma concentrations,Maximum plasma concentrations of pyridostigmine in the first and second groups of patients ranged from 12.4 to 64.5 ng per ml and 15.3 to 144.0 ng per ml respectively.,The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329157/),[ng] / [ml],15.3 to 144.0,175642,DB00545,Pyridostigmine
,11339294,flow-rate,"The compounds were extracted using C18 Sep-Pak Vac 3cc (500 mg) cartridges and separated using isocratic mobile phase of methanol, acetonitrile and water (pH 3.2) (10:40:50) at a flow-rate of 0.5 ml/min in a period of 12 min, and UV detection ranging between 240 and 280 nm.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ml] / [min],0.5,176397,DB00545,Pyridostigmine
,11339294,limits of detection,"The limits of detection for all analytes ranged between 20 and 50 ng/ml, while limits of quantitation were 100 ng/ml.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ng] / [ml],20 and 50,176398,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.1,176399,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.5,176400,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.9,176401,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,71.3,176402,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.7,176403,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.4,176404,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.1,176405,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,73.6,176406,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,74.3,176407,DB00545,Pyridostigmine
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.6,176408,DB00545,Pyridostigmine
,1865335,terminal half-life,"Pyridostigmine was characterized as a drug of relatively long terminal half-life (8.3 h +/- 2.1 SD), low systemic clearance (13 mL/min/kg +/- 1 SD) and high volumes of distribution (Vd lambda z, 8.7 L/kg +/- 1.9 SD and Vdss, 3.9 L/kg +/- 0.9 SD).",Pharmacokinetics of pyridostigmine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),h,8.3,178887,DB00545,Pyridostigmine
,1865335,systemic clearance,"Pyridostigmine was characterized as a drug of relatively long terminal half-life (8.3 h +/- 2.1 SD), low systemic clearance (13 mL/min/kg +/- 1 SD) and high volumes of distribution (Vd lambda z, 8.7 L/kg +/- 1.9 SD and Vdss, 3.9 L/kg +/- 0.9 SD).",Pharmacokinetics of pyridostigmine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),[ml] / [kg·min],13,178888,DB00545,Pyridostigmine
,1865335,volumes of distribution (Vd lambda z,"Pyridostigmine was characterized as a drug of relatively long terminal half-life (8.3 h +/- 2.1 SD), low systemic clearance (13 mL/min/kg +/- 1 SD) and high volumes of distribution (Vd lambda z, 8.7 L/kg +/- 1.9 SD and Vdss, 3.9 L/kg +/- 0.9 SD).",Pharmacokinetics of pyridostigmine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),[l] / [kg],8.7,178889,DB00545,Pyridostigmine
,1865335,Vdss,"Pyridostigmine was characterized as a drug of relatively long terminal half-life (8.3 h +/- 2.1 SD), low systemic clearance (13 mL/min/kg +/- 1 SD) and high volumes of distribution (Vd lambda z, 8.7 L/kg +/- 1.9 SD and Vdss, 3.9 L/kg +/- 0.9 SD).",Pharmacokinetics of pyridostigmine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),[l] / [kg],3.9,178890,DB00545,Pyridostigmine
greater,1865335,ratio of mean residence times,"The ratio of mean residence times in tissues and plasma was greater than 4, indicating a high affinity of peripheral tissues for the drug.",Pharmacokinetics of pyridostigmine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),,4,178891,DB00545,Pyridostigmine
,1865335,systemic availability,Pyridostigmine was slowly and incompletely bioavailable in these dogs; the systemic availability was 44.4% +/- 4.3 SD from the syrup and 33.6% +/- 9.5 SD from the tablet.,Pharmacokinetics of pyridostigmine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),%,44.4,178892,DB00545,Pyridostigmine
,1865335,systemic availability,Pyridostigmine was slowly and incompletely bioavailable in these dogs; the systemic availability was 44.4% +/- 4.3 SD from the syrup and 33.6% +/- 9.5 SD from the tablet.,Pharmacokinetics of pyridostigmine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865335/),%,33.6,178893,DB00545,Pyridostigmine
,837637,area under the plasma concentration-time curve,"In 3 myasthenic patients, the area under the plasma concentration-time curve was relatively constant for 4 hr after the same oral dose of pyridostigmine (60 mg).",Plasma pyridostigmine levels in patients with myasthenia gravis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837637/),h,4,180218,DB00545,Pyridostigmine
,837637,half-life,"After oral administration of pyridostigmine, the half-life of the drug in one subject (4.25 hr) was almost three times as great as after intramuscular administration in a different patient (1.49 hr).",Plasma pyridostigmine levels in patients with myasthenia gravis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837637/),h,4.25,180219,DB00545,Pyridostigmine
,837637,half-life,"After oral administration of pyridostigmine, the half-life of the drug in one subject (4.25 hr) was almost three times as great as after intramuscular administration in a different patient (1.49 hr).",Plasma pyridostigmine levels in patients with myasthenia gravis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837637/),h,1.49,180220,DB00545,Pyridostigmine
,9044164,volumes of distribution at steady state,Pharmacokinetics of these drugs are dose-independent and have similar volumes of distribution at steady state (0.4-0.6 L/kg various doses).,Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),[l] / [kg],0.4-0.6,191870,DB00545,Pyridostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,2019,191871,DB00545,Pyridostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,276,191872,DB00545,Pyridostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,26,191873,DB00545,Pyridostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,3.7,191874,DB00545,Pyridostigmine
,23387217,Tmax,"Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL.",[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),h,2,192546,DB00545,Pyridostigmine
,23387217,Cmax,"Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL.",[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),[min·μg] / [ml],22.79,192547,DB00545,Pyridostigmine
,23387217,AUC(0-infinity),"Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL.",[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),[min·μg] / [ml],7128.21,192548,DB00545,Pyridostigmine
,23387217,Cmax,"Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL.",[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),[μg] / [ml],6.00,192549,DB00545,Pyridostigmine
,23387217,AUC(0-infinity),"Pharmacokinetic parameters of mestinon-phospholipid complex were Tmax 2 h, Cmax 22.79 microg x min/mL and AUC(0-infinity) 7128.21 microg x min/mL, which were different from those of free mestinon--Tmax, 2 h, Cmax 6.00 microg/mL and AUC(0-infinity) 1772.36 microg x min/mL.",[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),[min·μg] / [ml],1772.36,192550,DB00545,Pyridostigmine
,23387217,relative bioavailability,The relative bioavailability of mestinon-phospholipid complex was 410.98% of free mestinon.,[Pharmacokinetics of mestinon-phospholipid complex in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387217/),%,410.98,192551,DB00545,Pyridostigmine
,1783998,maximum serum concentration,The average maximum serum concentration (50 ng/mL) was reached in 29 min.,Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],50,240801,DB00545,Pyridostigmine
,1783998,volume of distribution,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240802,DB00545,Pyridostigmine
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240803,DB00545,Pyridostigmine
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ml] / [kg·min],19.4,240804,DB00545,Pyridostigmine
,1783998,maximum concentration,"The percentage of diazepam unbound to serum proteins was 4.6% and, therefore, the maximum concentration of free diazepam was 2.3 ng/mL.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],2.3,240805,DB00545,Pyridostigmine
,3987173,oral availability,"As determined from the AUC ratio, oral availability was 11.5% to 18.9% (means = 14.3%).",Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987173/),%,11,250962,DB00545,Pyridostigmine
,3987173,oral availability,"As determined from the AUC ratio, oral availability was 11.5% to 18.9% (means = 14.3%).",Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987173/),%,18,250963,DB00545,Pyridostigmine
,3987173,oral availability,"As determined from the AUC ratio, oral availability was 11.5% to 18.9% (means = 14.3%).",Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987173/),%,14.3,250964,DB00545,Pyridostigmine
,3987173,t 1/2,"Mean t 1/2 of the plasma level decline after oral dosing was 200 minutes, twice as long as the terminal elimination t1/2 after intravenous infusion (97 minutes).",Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987173/),min,200,250965,DB00545,Pyridostigmine
,3987173,terminal elimination t1/2,"Mean t 1/2 of the plasma level decline after oral dosing was 200 minutes, twice as long as the terminal elimination t1/2 after intravenous infusion (97 minutes).",Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987173/),min,97,250966,DB00545,Pyridostigmine
,8845827,Vdss,"Four ChE inhibitors have similar Vdss values within the range of 0.3-0.7 l/kg, which is similar to the muscle/plasma concentration ratio of these drugs.",Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),[l] / [kg],0.3-0.7,257133,DB00545,Pyridostigmine
,8845827,liver,The liver or kidney to plasma concentration ratio of all ChE inhibitors at 20min after i.v. administration ranged from 5 to 15.,Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),,5 to 15,257134,DB00545,Pyridostigmine
,8845827,kidney to plasma concentration ratio,The liver or kidney to plasma concentration ratio of all ChE inhibitors at 20min after i.v. administration ranged from 5 to 15.,Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),,5 to 15,257135,DB00545,Pyridostigmine
,2493023,peak,"In the normal subjects, a similar dose of GHRH induced a GH peak of 24.3 +/- 7.1 micrograms/L, and the GHRH-stimulated peak was significantly higher (56.2 +/- 16.8 micrograms/L) after pyridostigmine administration.",Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493023/),[μg] / [l],24.3,272868,DB00545,Pyridostigmine
,2493023,peak,"In the normal subjects, a similar dose of GHRH induced a GH peak of 24.3 +/- 7.1 micrograms/L, and the GHRH-stimulated peak was significantly higher (56.2 +/- 16.8 micrograms/L) after pyridostigmine administration.",Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493023/),[μg] / [l],56.2,272869,DB00545,Pyridostigmine
,2493023,peak plasma GH level,"In the normal subjects the mean peak plasma GH level after pyridostigmine was 12.5 +/- 3.1 micrograms/L, and in the obese subjects it was 4.6 +/- 1.3 micrograms/L.",Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493023/),[μg] / [l],12.5,272870,DB00545,Pyridostigmine
,2493023,peak plasma GH level,"In the normal subjects the mean peak plasma GH level after pyridostigmine was 12.5 +/- 3.1 micrograms/L, and in the obese subjects it was 4.6 +/- 1.3 micrograms/L.",Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493023/),[μg] / [l],4.6,272871,DB00545,Pyridostigmine
